Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4852386 | 0.99 | ALDH1A1 (0.50) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| SCHEMBL6035340 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| Hydrochloric Acid SCHEMBL4861101 | 0.91 | ALDH1A1 (0.50) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| SCHEMBL6035081 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| Hydrochloric Acid SCHEMBL4859060 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| SCHEMBL6034277 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| SCHEMBL6035826 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTRXFP1KDM4ECASP3 | |
| SCHEMBL6035904 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MAPTRXFP1TP53KDM4E | |
| Hydrochloric Acid SCHEMBL4856892 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 | |
| SCHEMBL6035104 | 0.85 | ALDH1A1 (0.54) | ALDH1A1MAPTRXFP1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | ALDH1A1 118/4885MAPT 1965/4885RXFP1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.